We are live on ! Find out more
AWGLSCP

ABG-WTT Global Life Science Capital Partners Portfolio holdings

AUM $12.3M
1-Year Est. Return 3.13%
This Fund
S&P 500
This Quarter Est. Return
+20.5%
1 Year Est. Return
-3.13%
3 Year Est. Return
+108.96%
5 Year Est. Return
-90.91%
10 Year Est. Return
–
AUM
$20.1M
AUM Growth
-$9.85M
Cap. Flow
-$14.7M
Cap. Flow %
-73.18%
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.66B
$18.7M 92.93%
495,526
-419,975
-46% -$14.7M
RPID icon
2
Rapid Micro Biosystems
RPID
$86.2M
$924K 4.59%
1,038,296
– –
LUNG icon
3
Pulmonx
LUNG
$87.6M
$499K 2.48%
60,204
– –

Similar funds

M
MetLife New York $12.3M AUM 29% 1-Year Est. Return
MAMNY
Marathon Asset Management (New York) New York $12M AUM 8.79% 1-Year Est. Return
IWM
Immaculate Wealth Management Mesa, Arizona $12.7M AUM
VH
Vitol Holding Rotterdam, Netherlands $11.9M AUM 27.28% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
CCM
Crabel Capital Management Los Angeles, California $10.8M AUM 3.34% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $10.8M AUM 61.97% 1-Year Est. Return

ABG-WTT Global Life Science Capital Partners's Q3 2024 Portfolio in Review

As of Q3 2024, ABG-WTT Global Life Science Capital Partners held 3 positions worth $20.1M, down 33% from $30M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ABG-WTT Global Life Science Capital Partners withdrew a net $14.7M in Q3 2024, reducing 1 holding. Its largest reduction was CG Oncology, cutting an estimated $14.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ABG-WTT Global Life Science Capital Partners's biggest Q3 2024 reduction was CG Oncology, cutting an estimated $14.7M.
  • ABG-WTT Global Life Science Capital Partners's ten largest holdings make up 100% of its $20.1M portfolio in Q3 2024.
  • ABG-WTT Global Life Science Capital Partners opened 0 new positions and closed 0 in Q3 2024.
  • ABG-WTT Global Life Science Capital Partners's portfolio value fell 33% quarter-over-quarter to $20.1M.

Based on ABG-WTT Global Life Science Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.